Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 43Melanoma 19Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 9Glioblastoma 8Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Pancreatic Neoplasms 7Ovarian Neoplasms 7Gliosarcoma 7Lung Neoplasms 6Histiocytoma, Malignant Fibrous 6Carcinoma, Renal Cell 6Osteosarcoma 5Liposarcoma 5Head and Neck Neoplasms 5Carcinoma, Hepatocellular 5Uterine Cervical Neoplasms 4Sarcoma, Synovial 4Sarcoma, Kaposi 4Neurofibrosarcoma 4Lymphoma 4Hemangiosarcoma 4Carcinoma, Merkel Cell 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3Recurrence 3

Interventions

Nivolumab 2pembrolizumab 1pazopanib 1elacestrant 1Specimen Handling 1Radiotherapy 1Radiation 1RAD1901 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Ifosfamide 1Doxorubicin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Perivascular Epithelioid Cell Neoplasms × pembrolizumab × Sarcoma × Clear all
NCT07089992 2026-05-14

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
32 enrolled
Sarcoma

Liposarcoma, Sarcoma, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡